Novavax Inc. (NVAX) shares surged 7.12% in pre-market trading on Tuesday following the announcement of a license agreement with Pfizer. The agreement, disclosed in an SEC filing, is expected to bolster Novavax's position in the pharmaceutical market.
The collaboration with Pfizer, a global leader in the industry, is seen as a strategic move that could enhance Novavax's product pipeline and revenue potential. Investors reacted positively to the news, driving the stock higher in early trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments